Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020
Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Databa...
Saved in:
Published in | Cancer research and treatment Vol. 55; no. 2; pp. 385 - 399 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Cancer Association
01.04.2023
대한암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1598-2998 2005-9256 2005-9256 |
DOI | 10.4143/crt.2023.447 |
Cover
Abstract | Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. |
---|---|
AbstractList | Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.PURPOSEThe current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.Materials and MethodsIncidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.RESULTSThe number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.CONCLUSIONIn 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020. Materials and Methods Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea. Results The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020. Conclusion In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. KCI Citation Count: 15 The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020. Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea. The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020. In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future. |
Author | Kang, Mee Joo Park, Eun Hye Kim, Hye-Jin Jung, Kyu-Won Bang, So Hyun Yun, E Hwa Seo, Hong Gwan Kong, Hyun-Joo Choi, Seo Hyun Im, Jeong-Soo |
AuthorAffiliation | Korea Central Cancer Registry, National Cancer Center, Goyang, Korea |
AuthorAffiliation_xml | – name: Korea Central Cancer Registry, National Cancer Center, Goyang, Korea – name: 1 Korea Central Cancer Registry, National Cancer Center, Goyang, Korea – name: 3 National Cancer Control Institute, National Cancer Center, Goyang, Korea – name: 4 National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea – name: 2 Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea |
Author_xml | – sequence: 1 givenname: Mee Joo surname: Kang fullname: Kang, Mee Joo – sequence: 2 givenname: Kyu-Won surname: Jung fullname: Jung, Kyu-Won – sequence: 3 givenname: So Hyun surname: Bang fullname: Bang, So Hyun – sequence: 4 givenname: Seo Hyun surname: Choi fullname: Choi, Seo Hyun – sequence: 5 givenname: Eun Hye surname: Park fullname: Park, Eun Hye – sequence: 6 givenname: E Hwa surname: Yun fullname: Yun, E Hwa – sequence: 7 givenname: Hye-Jin surname: Kim fullname: Kim, Hye-Jin – sequence: 8 givenname: Hyun-Joo surname: Kong fullname: Kong, Hyun-Joo – sequence: 9 givenname: Jeong-Soo surname: Im fullname: Im, Jeong-Soo – sequence: 10 givenname: Hong Gwan surname: Seo fullname: Seo, Hong Gwan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36915245$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002948880$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNptkU1PGzEQhi0EKoH21nO1x6rKpvb4a90LQhHQCKpWfJwtx3GKy8amthOJf4-XUFSqyofxaJ55Z-z3AO2GGBxC7wmeMMLoZ5vKBDDQCWNyB40AY94q4GIXjQhXXQtKdfvoIOdfGAtGJXmD9qlQhAPjI3Q5NcG61FwVU3wu3ubGh-Y8Jme-NLNg_cLV-rj5FlMxvS8P4-ZqnTZ-Y_pxY8Ki-ZFcvQ_Q0FgXwW_R3tL02b17jofo5vTkevq1vfh-NpseX7SWAS6tUUwyACJg3i1BSiaNAYm5Erw-C9cUCwWC22FZCoRSBXTOrATFTQeOHqJPW92QlvrOeh2Nf4o_o75L-vjyeqYJBsIIpxU-2sL36_nKLawLJZle3ye_MunhqfV1JfjbKrSpCvVIJarCx2eFFH-vXS565bN1fW-Ci-usQXaiI7TjXUU__D3sZcqfb6_AeAvYFHNObvmCEKwHV3V1VQ-u6upqxeEf3PrBrzis6vv_Nz0CH1WhfA |
CitedBy_id | crossref_primary_10_1186_s12888_025_06602_z crossref_primary_10_25055_JKSRNT_2024_15_2_49 crossref_primary_10_1186_s12885_025_13513_5 crossref_primary_10_3390_nu16071048 crossref_primary_10_3389_fonc_2024_1403120 crossref_primary_10_1007_s00520_024_08341_5 crossref_primary_10_17998_jlc_2024_08_13 crossref_primary_10_1002_ijc_34935 crossref_primary_10_15279_kpba_2023_28_4_131 crossref_primary_10_1245_s10434_024_16792_7 crossref_primary_10_1016_j_nutres_2024_09_003 crossref_primary_10_3390_cancers15235606 crossref_primary_10_1007_s00330_025_11461_z crossref_primary_10_1016_j_apjon_2024_100483 crossref_primary_10_4166_kjg_2024_091 crossref_primary_10_1016_j_heliyon_2024_e37046 crossref_primary_10_5468_ogs_23208 crossref_primary_10_3390_cimb47020088 crossref_primary_10_3390_cancers16162923 crossref_primary_10_3390_healthcare11243171 crossref_primary_10_1016_j_prnil_2024_12_002 crossref_primary_10_21032_jhis_2023_48_S1_S15 crossref_primary_10_3346_jkms_2024_39_e320 crossref_primary_10_5534_wjmh_230104 crossref_primary_10_12771_emj_2024_e53 crossref_primary_10_22465_juo_234600480024 crossref_primary_10_3892_ol_2024_14668 crossref_primary_10_22465_juo_244600220011 crossref_primary_10_5009_gnl240111 crossref_primary_10_4111_icu_20230333 crossref_primary_10_3857_roj_2023_00955 crossref_primary_10_1007_s00520_024_08347_z crossref_primary_10_1016_j_esmoop_2024_103969 crossref_primary_10_4178_epih_e2023101 crossref_primary_10_3390_electronics14050880 crossref_primary_10_5124_jkma_2024_67_7_484 crossref_primary_10_1109_ACCESS_2023_3296710 crossref_primary_10_4174_astr_2023_105_6_376 crossref_primary_10_3389_fonc_2024_1395473 crossref_primary_10_4143_crt_2024_207 crossref_primary_10_1007_s13187_024_02502_0 crossref_primary_10_3947_ic_2024_0057 crossref_primary_10_3390_cancers15133371 crossref_primary_10_5853_jos_2023_03279 crossref_primary_10_1007_s10549_024_07571_9 crossref_primary_10_1007_s11764_024_01642_y crossref_primary_10_3389_fpubh_2023_1256525 crossref_primary_10_3390_cancers15164134 crossref_primary_10_1111_joim_20071 crossref_primary_10_1016_j_jtho_2024_12_006 crossref_primary_10_3390_ijms241814355 crossref_primary_10_52927_jdcr_2024_12_2_53 crossref_primary_10_1016_j_canep_2024_102594 crossref_primary_10_4143_crt_2024_325 crossref_primary_10_1016_j_radonc_2023_109982 crossref_primary_10_1016_j_puhe_2024_11_015 crossref_primary_10_1080_09637486_2024_2314678 crossref_primary_10_3349_ymj_2023_0009 crossref_primary_10_4132_jptm_2024_07_29 crossref_primary_10_1007_s00520_025_09169_3 crossref_primary_10_1177_17588359241254218 crossref_primary_10_3892_mi_2025_214 crossref_primary_10_4178_epih_e2023089 crossref_primary_10_1016_j_ejso_2024_108515 crossref_primary_10_1016_j_diagmicrobio_2024_116433 crossref_primary_10_1038_s41598_024_83048_5 crossref_primary_10_1017_S1478951523001815 crossref_primary_10_3904_kjm_2024_99_2_96 crossref_primary_10_1002_cam4_6660 crossref_primary_10_4111_icu_20240047 crossref_primary_10_3349_ymj_2023_0014 crossref_primary_10_1016_j_pec_2025_108674 crossref_primary_10_1158_1940_6207_CAPR_24_0154 crossref_primary_10_1017_S000711452400206X crossref_primary_10_4178_epih_e2023077 crossref_primary_10_1007_s13258_023_01408_3 crossref_primary_10_21593_kjhno_2023_39_1_1 crossref_primary_10_1097_MD_0000000000037639 crossref_primary_10_4143_crt_2024_421 crossref_primary_10_3390_cancers15235516 crossref_primary_10_5977_jkasne_2024_30_3_290 crossref_primary_10_3348_kjr_2024_0866 crossref_primary_10_1002_cncr_35711 crossref_primary_10_1016_j_ygyno_2024_09_015 crossref_primary_10_3390_cancers16132486 crossref_primary_10_4178_epih_e2024074 crossref_primary_10_1177_16094069241247476 crossref_primary_10_15747_ACNM_2024_16_1_10 crossref_primary_10_3390_cancers16244278 crossref_primary_10_52927_jdcr_2024_12_2_82 crossref_primary_10_15747_ACNM_2024_16_2_66 crossref_primary_10_4143_crt_2024_016 crossref_primary_10_4174_astr_2024_107_2_59 crossref_primary_10_11106_ijt_2023_16_2_143 crossref_primary_10_1002_cam4_70030 crossref_primary_10_1097_MD_0000000000037732 crossref_primary_10_1200_GO_23_00352 crossref_primary_10_3393_ac_2024_00388_0055 crossref_primary_10_4174_astr_2025_108_1_20 crossref_primary_10_3390_jpm14101058 crossref_primary_10_1111_jgh_16493 crossref_primary_10_3904_kjm_2023_98_6_283 crossref_primary_10_1038_s41598_024_75493_z crossref_primary_10_3390_cancers15225414 crossref_primary_10_3390_medicina60091509 crossref_primary_10_11620_IJOB_2024_49_1_18 crossref_primary_10_4093_dmj_2024_0277 crossref_primary_10_1038_s41598_025_92951_4 crossref_primary_10_3390_cancers15245809 crossref_primary_10_1016_j_heliyon_2024_e28121 crossref_primary_10_1038_s41416_024_02847_9 crossref_primary_10_51666_fs_2023_3_e5 crossref_primary_10_1186_s12885_023_11736_y crossref_primary_10_22465_juo_234600560028 crossref_primary_10_1186_s12885_025_13819_4 |
Cites_doi | 10.4143/crt.2005.37.6.325 10.1038/s41598-022-15778-3 10.1001/jamaoncol.2022.2617 10.3322/caac.21708 |
ContentType | Journal Article |
Copyright | Copyright © 2023 by the Korean Cancer Association 2023 |
Copyright_xml | – notice: Copyright © 2023 by the Korean Cancer Association 2023 |
CorporateAuthor | The Community of Population-Based Regional Cancer Registries Community of Population-Based Regional Cancer Registries |
CorporateAuthor_xml | – name: The Community of Population-Based Regional Cancer Registries – name: Community of Population-Based Regional Cancer Registries |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.4143/crt.2023.447 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2005-9256 |
EndPage | 399 |
ExternalDocumentID | oai_kci_go_kr_ARTI_10214153 PMC10101796 36915245 10_4143_crt_2023_447 |
Genre | Journal Article |
GeographicLocations | Republic of Korea |
GeographicLocations_xml | – name: Republic of Korea |
GrantInformation_xml | – fundername: Ministry of Health and Welfare grantid: 2260020 – fundername: National Cancer Center grantid: 2211110 – fundername: Health Promotion Fund of the Ministry of Health & Welfare grantid: 2260020; 2211110 – fundername: National Cancer Center, Republic of Korea |
GroupedDBID | --- 29B 5-W 53G 8JR 9ZL AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P HYE OK1 RPM TR2 C1A CGR CUY CVF ECM EIF NPM 7X8 5PM M~E |
ID | FETCH-LOGICAL-c420t-a947422162b8f27747aa2705965143047a069265c369132133923b4c7295a82e3 |
ISSN | 1598-2998 2005-9256 |
IngestDate | Sat Apr 06 03:24:33 EDT 2024 Thu Aug 21 18:38:04 EDT 2025 Thu Jul 10 22:52:38 EDT 2025 Mon Jul 21 05:54:09 EDT 2025 Thu Apr 24 23:10:15 EDT 2025 Tue Jul 01 03:18:52 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Prevalence Survival Mortality Neoplasms Incidence Korea |
Language | English |
License | This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c420t-a947422162b8f27747aa2705965143047a069265c369132133923b4c7295a82e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Regional Cancer Registry Committee Chang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Cancer Registry, Ulsan University Hospital), Yong-Dae Kim (Chungbuk Cancer Registry, Chungbuk National University Hospital), Young-Taek Kim (Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital), Chul Min Park (Jeju Cancer Registry, Jeju National University and Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Jeonbuk National University Hospital), Kyu-Hyoung Lim (Kangwon Cancer Registry, Kangwon National University and Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University), Sun-Seog Kweon (Gwangju/Jeonnam Cancer Registry, Chonnam National University Hwasun Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Ki-Soo Park (Gyeongnam Cancer Registry, Gyeongsang National University and Hospital). |
ORCID | 0000-0002-4389-9701 0000-0002-9289-3808 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10101796 |
PMID | 36915245 |
PQID | 2786813858 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10214153 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10101796 proquest_miscellaneous_2786813858 pubmed_primary_36915245 crossref_primary_10_4143_crt_2023_447 crossref_citationtrail_10_4143_crt_2023_447 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-04-01 |
PublicationDateYYYYMMDD | 2023-04-01 |
PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Cancer research and treatment |
PublicationTitleAlternate | Cancer Res Treat |
PublicationYear | 2023 |
Publisher | Korean Cancer Association 대한암학회 |
Publisher_xml | – name: Korean Cancer Association – name: 대한암학회 |
References | Fritz (ref8) 2013 (ref2) 2021 Young (ref12) 2001 Ferlay (ref1) 2020 Ajiki (ref7) 1998 (ref9) 1994 ref4 Ferlay (ref10) 2020 ref3 (ref11) 2017 ref6 Segi (ref14) 1960 ref5 (ref13) 2017 (ref16) 2016 Ederer (ref15) 1959 |
References_xml | – year: 2017 ident: ref13 – year: 2020 ident: ref1 – year: 2017 ident: ref11 – year: 1960 ident: ref14 – ident: ref6 doi: 10.4143/crt.2005.37.6.325 – year: 2020 ident: ref10 – volume-title: SEER summary staging manual 2000: codes and coding instructions year: 2001 ident: ref12 – ident: ref4 doi: 10.1038/s41598-022-15778-3 – year: 2016 ident: ref16 – year: 2021 ident: ref2 – ident: ref5 doi: 10.1001/jamaoncol.2022.2617 – year: 2013 ident: ref8 – year: 1994 ident: ref9 – ident: ref3 doi: 10.3322/caac.21708 – start-page: 1011 volume-title: Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index year: 1998 ident: ref7 – year: 1959 ident: ref15 |
SSID | ssj0064371 |
Score | 2.6029043 |
Snippet | Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in... The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.... The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 385 |
SubjectTerms | COVID-19 - epidemiology Humans Incidence Neoplasms Prevalence Republic of Korea - epidemiology Special Survival Rate 의학일반 |
Title | Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36915245 https://www.proquest.com/docview/2786813858 https://pubmed.ncbi.nlm.nih.gov/PMC10101796 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002948880 |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Cancer Research and Treatment, 2023, 55(2), , pp.385-399 |
journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2005-9256 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064371 issn: 1598-2998 databaseCode: ABDBF dateStart: 20120301 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2005-9256 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064371 issn: 1598-2998 databaseCode: DIK dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2005-9256 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064371 issn: 1598-2998 databaseCode: 5-W dateStart: 20010101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central (WRLC) customDbUrl: eissn: 2005-9256 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064371 issn: 1598-2998 databaseCode: RPM dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe6TkK8IL7p-FAQ8NSmSxzHSXhbC1MBlQe2ib1ZieuyaiiZSoM03vm_ubMdN62KNHjph2vHSn-X85199ztCXs_oTALsuc9nReCzPAA9CAutH2dMBmlRzDOdPjb9zCdn7ON5fN7p_G5FLdWrYih_7cwr-R9UoQ1wxSzZf0DWXRQa4DPgC6-AMLzeCOMxQrbUBqPlW16U_U8V2IHo6MOjbyqG6k1PbWbbEgAnNSiIn5rq32YLIOm3fsbhAjSgQdtmtbNYWiCTCefi053CtvvOU4WpZpULzGl0yXXtf12f-I-aXeqqP7muXfP4otLBBSeq1W63JGjUimSxWjTD1A5TXnqodJumPM2oYRFvVK9h6LUiRlt6NDJ1fOySHJkaStvanoGtBxDJJcbE0mjIDHfnJqn21mLnQhDB-cHxAkYLHC1g9B7ZpwnntEv2j0bvRsfNko6Hm4Z4196XyaDA8Yft2Tdsm71yOd_ltmxH37bMmdO75I71Q7wjI1T3SEeV98mtqY20eEC-GNS9tWx5i9LTsvXWc5I18JxcDbxGqgYeSIi3likciDL1kJwdvz8dT3xbf8OXjAYrP89YwigNOS3SOQU_IclzmmC9JrSyA_ga8IzyWEY8CyMaRmBrRwWT4K_FeUpV9Ih0y6pUT4iXKugzi9V8Dh4wS5IU97rkLOJKqSRUskf6zT8npCWnxxop38UunHrkjet9ZUhZ_tLvFYAgLuVCIIs6vn-rxOVSgK_4Qeii9rDg98jLBiQBuhUPzPJSVfUPQZOUpyEenffIYwOamw_vOaYs7pF0A07XAWfc_KVcXGj-9jDQ6yA_uOFtPCW310_ZM9JdLWv1HEzhVfHCCuofJ7mt0w |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+Statistics+in+Korea%3A+Incidence%2C+Mortality%2C+Survival%2C+and+Prevalence+in+2020&rft.jtitle=Cancer+research+and+treatment&rft.au=Kang%2C+Mee+Joo&rft.au=Jung%2C+Kyu-Won&rft.au=Bang%2C+So+Hyun&rft.au=Choi%2C+Seo+Hyun&rft.date=2023-04-01&rft.issn=1598-2998&rft.eissn=2005-9256&rft.volume=55&rft.issue=2&rft.spage=385&rft.epage=399&rft_id=info:doi/10.4143%2Fcrt.2023.447&rft.externalDBID=n%2Fa&rft.externalDocID=10_4143_crt_2023_447 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon |